FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
hours per respons	e 0.5				

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Ty	pe Response	es)													
Name and Address of Reporting Person * Price Ben Gil			2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]					JI	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455			3. Date of Earliest Transaction (Month/Day/Year) 11/29/2018						Officer (give	title below)	Other	(specify below)			
(Street) ROCKVILLE, MD 20850			4. If Amendment, Date Original Filed(Month/Day/Year)					_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(Cit	y)	(State)	(Zip)	Table I - Non-Derivative Securities Acqui					s Acquired,	ired, Disposed of, or Beneficially Owned					
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)		on I	Date, if Co (In		(A (In	Securities Acquilibrium (A) or Disposed custr. 3, 4 and 5) (A) or (D)	of (D) Own Tran		ecurities Being Reported	I O FO D OI (I	wnership orm: Birect (D) Ormit Indirect (I	eneficial wnership
Reminder:	Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
	Conversion	3. Transaction Date Securition Date (Month/Day/Year) 3. Transaction Date Execution Date, if Code (Month/Day/Year) (Month/Day/Year) 3. Transaction Date Exercisable and Execution Date, if Transaction Code (Month/Day/Year) (Month/Day/Year) (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed		7. Title and of Underly Securities	Title and Amount Underlying		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownershi Form of Derivative Security: Direct (D or Indirect)	(Instr. 4)						
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (right to buy)	\$ 1.10	11/29/2018		A		112,878		<u>(1)</u>	11/29/2028	Common Stock	112,878	\$ 0	112,878	D	

Reporting Owners

Donordino Omero Norre / Address	Relationships					
Reporting Owner Name / Address		10% Owner	Officer	Other		
Price Ben Gil C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	Х					

Signatures

/s/ Douglas J. Swirsky, as attorney-in-fact for Ben Gil Price	12/03/2018	
Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options will vest and become exercisable based on the following schedule: 37,626 on November 29, 2019, 37,626 on November 29, 2020, and 37,626 on November 29, 2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.